Thrombocytopenia

Interleukin Therapy May Negate Need for Platelet Transfusions

Published in Blood Weekly, May 13th, 1996

A strategy designed to combat chemotherapy-induced thrombocytopenia may render the need for platelet transfusions unnecessary following subsequent chemotherapy cycles.

The protocol has involved use of recombinant human interleukin-11 (rhIL-11), a growth factor that stimulates production of platelets. Dr. Isidore Tepler, Beth Israel Hospital, Boston, Massachusetts, was lead author of a rapid communication on rhIL-11 that was published in the May 1, 1996, issue of Blood (Blood 1996;87:3607-3614).

Tepler's group randomized 93 cancer patients who had already received platelet transfusions for severe chemotherapy-induced thrombocytopenia to therapy with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1996-05-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry